SEA-CD70

SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody that targets the human CD70 antigen. Developed using a sugar-engineered antibody (SEA) platform, it is designed to enhance effector functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). By binding to CD70—which is aberrantly expressed on malignant myeloid blasts but largely absent from healthy hematopoietic progenitor cells—SEA-CD70 aims to eliminate cancerous cells while sparing normal tissue. Additionally, it may block the interaction between CD70 and its ligand CD27, potentially disrupting tumor cell survival signals and modulating immune responses to limit immune evasion and increase antigen-specific T cell activity. The drug is under clinical investigation for use in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), particularly in relapsed or refractory cases where treatment options are limited[1][2][3][5][6].